@FierceMedDev: OraSure gets FDA nod for emergency use of rapid Ebola test. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: Intuitive awards grants to support training of its da Vinci robot using virtual reality. Article | Follow @VarunSaxena2
@EmilyWFierce: The FDA just approved the first 3-D printed drug. More from MedScape | Follow @EmilyWFierce
> Zimmer Biomet ($ZMH) was slapped with a $9.2 million verdict from a California jury for a man who had to replace a metal-on-metal Durom Cup. More
> The American Medical Association has given Gynesonics a CPT code for its transcervical uterine fibroid ablation device, which should help ease reimbursement processes. It's an alternative to surgery involving the highly controversial power morcellator. More
> The FDA has classified external upper esophageal sphincter (UES) compression devices as Class II. More
Biotech News
@FierceBiotech: ICYMI: Sorrento buys into biosimilars with a Chinese antibody deal. Story | Follow @FierceBiotech
@JohnCFierce: How to lose a billion dollars -- $AXON cap down to $1.28B, down about a billion from its IPO. | Follow @JohnCFierce
@DamianFierce: $SHPG first proposed a merger on July 10, meaning $BXLT lasted nine whole days before someone tried to buy it. | Follow @DamianFierce
> After years on the slide, things are looking up in biopharma R&D, report says. More
> Regeneron ups its research budget by 32% with eyes on new blockbusters. Story
> Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pipeline. Article
Pharma News
@FiercePharma: Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: Realizing that a proposed Shire deal with a pharma spinoff in the Chicago suburbs is exactly what this summer was missing. $SHPG $BXLT $ABBV | Follow @CarlyHFierce
> Lilly faces first trial over claims of Cymbalta withdrawal symptoms. Report
> Deal-minded Shire offers $30B for new spinoff Baxalta in public bid. News
Drug Delivery News
> Recommended chemotherapy administration method found underutilized. Report
> Emergent BioSolutions launches autoinjector to protect against chemical weapons attacks. Item
> NanoSmart's targeted cancer killer gains another orphan designation for Ewing's sarcoma. More
> Dauntless gets $12M in Series A to develop cancer med using intranasal platform. Story
> Northwestern bags $17.5M from NIH to develop implant for delivery of drugs that prevent HIV. Article
Pharma Manufacturing News
> GSK beefing up in U.S. drug and inhaler plant. Article
> FDA looks at Baxter Mexico plant for more saline supply. Report
> Wockhardt retrieves millions and millions of drugs in effort to win back FDA approval. Story
> FDA approves seizure drug made with 3-D technology. Item
> Generics maker Amneal revamping former J&J plant in Ireland. Article
Pharma Asia News
> Takeda submits post-marketing Actos study that shows no link to bladder cancer. News
> Merck eyes opportunity for omarigliptin filing with Japan's PMDA. Report
> Bayer sees Q2 bright spots in China pharma, but consumer health is more complicated. Story
> Sales of diabetes drugs in Japan are a key H2 performance gauge, Sanofi CEO says. More
> Amgen says Vectibix sales in Japan got Q2 boost on shipments to Takeda. Article